At Aprimus Diagnostics, we are advancing health monitoring and diagnostics with cutting-edge technology designed for professional and consumer use. We have designed our new product to directly tackle key patient issues identified through years of research and development:
Aprimus Diagnostics sells a Test Kit that includes: the disposable smart meter and 20 immunochromatographic tests calibrated for the specific lot of chemistry. For patients, a single test will be administered in a doctor's office.
The first product Aprimus will be bringing to market will be the D-Dimer test. D-Dimer is a protein fragment found within the bloodstream after a blood clot is broken down. The Aprimus D-Dimer test will identify and quantify the coagulation status of patients with deep vein thrombosis (DVT) and pulmonary embolism (PE).
This test has other new uses, e.g., being mandated in Pregnancy and emerging treatment for preventing adverse reactions to Vaccinations.
Additional biomarker tests for diagnosing other critical disease will follow. Such as TUMOR MARKERS for Cancer detection necessary for earlier treatment and with new forecasted AI driven medication being developed.
An Aprimus D-Dimer test is similar to other venipuncture or fingerstick techniques, where a blood sample is collected and gets dropped into the sample well of the cassette tray, followed by a few drops of buffer solution. The cassette tray slides inside the smart meter where the Aprimus proprietary quantitative lateral flow assay (qLFA) test is performed.
The turnaround time for results is about 15 minutes.
D-Dimer will be available only thru a professional medical healthcare provider or office. Aprimus will be working on future self-test products.
Aprimus expects test kits to be in the public markets by 2026.
Aprimus has received US Patent #12,055,479 for the smart meter (August 2024). Aprimus Diagnostics will be working thru the regulatory processes for CE and 510k for the remainder of 2025 and into 2026.
The Aprimus product design is unique and is designed to provide the most accurate and precise quantitative reading for disease biomarkers. The access to the numerical results can help professionals make frequent monitoring easier - saving patients valuable time scheduling appointments and avoiding extra costs for intermittent medications or being hospitalized. Most important, Aprimus can help people live longer through better healthcare and advanced diagnostics!
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.